World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
43
Citations
6393
World Ranking
4854
National Ranking
2174

Richard B. Bankert publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Richard B. Bankert sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 159 publications — 19th percentile

19% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Richard B. Bankert D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Richard B. Bankert sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 43 D-Index — 2nd percentile

2% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Richard B. Bankert is affiliated with the University at Buffalo, State University of New York in the United States. Their research primarily spans the fields of Immunology and Microbiology, Biochemistry, Genetics and Molecular Biology, and Medicine, with a notable focus on Immunology in particular.

Their work extensively addresses topics related to extracellular vesicles in disease, immunotherapy and immune responses, as well as phagocytosis and immune regulation. Other areas of research include microRNA in disease regulation, immune cell function and interaction, galectins and cancer biology, and SARS-CoV-2 and COVID-19 research.

Richard B. Bankert has contributed to several peer-reviewed publications, including:

  • Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments, 2021, Journal for ImmunoTherapy of Cancer
  • Tumor-Associated Exosomes: A Potential Therapeutic Target for Restoring Anti-Tumor T Cell Responses in Human Tumor Microenvironments, 2021, Cells
  • Exosomes Represent an Immune Suppressive T Cell Checkpoint in Human Chronic Inflammatory Microenvironments, 2020, Immunological Investigations
  • Rational design of a nanoparticle platform for oral prophylactic immunotherapy to prevent immunogenicity of therapeutic proteins, 2021, Scientific Reports
  • Preclinical evaluation of cancer immune therapy using patient-derived tumor antigen-specific T cells in a novel xenograft platform, 2021, Clinical & Translational Immunology

Their frequent coauthors include:

  • Gautam N. Shenoy
  • Maulasri Bhatta
  • Jenni Loyall
  • Raymond J. Kelleher
  • Sathy V. Balu-Iyer

Richard B. Bankert's publications have appeared in several scientific journals such as the Journal for ImmunoTherapy of Cancer, Cells, Immunological Investigations, Scientific Reports, and Clinical & Translational Immunology.

Best Publications

  • Integrin alpha 2 beta 1 is upregulated in fibroblasts and highly aggressive melanoma cells in three-dimensional collagen lattices and mediates the reorganization of collagen I fibrils.

    C E Klein;D Dressel;T Steinmayer;C Mauch

  • Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells.

    Michael R. Nazareth;Lori Broderick;Michelle R. Simpson-Abelson;Raymond J. Kelleher

  • Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a “vaccinal effect” of rituximab

    Shannon P. Hilchey;Ollivier Hyrien;Tim R. Mosmann;Alexandra M. Livingstone

  • In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity.

    Nejat K. Egilmez;Yong S. Jong;Michael S. Sabel;Jules S. Jacob

  • Cancer Immunotherapy with Interleukin 12 and Granulocyte-Macrophage Colony-stimulating Factor-encapsulated Microspheres: Coinduction of Innate and Adaptive Antitumor Immunity and Cure of Disseminated Disease

    Hank C. Hill;Thomas F. Conway;Michael S. Sabel;Yong S. Jong

  • Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes.

    Scott S. Williams;Thomas R. Alosco;Eric Mayhew;Danilo D. Lasic

  • Antibody Targeting of Doxorubicin-loaded Liposomes Suppresses the Growth and Metastatic Spread of Established Human Lung Tumor Xenografts in Severe Combined Immunodeficient Mice

    Masahiko Sugano;Nejat K. Egilmez;Sandra J. Yokota;Fang-An Chen

  • Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment.

    Kelly L. Singel;Tiffany R. Emmons;Anm Nazmul H. Khan;Paul C. Mayor

  • Long-Term Engraftment and Expansion of Tumor-Derived Memory T Cells Following the Implantation of Non-Disrupted Pieces of Human Lung Tumor into NOD-scid IL2Rγnull Mice

    Michelle R Simpson-Abelson;Gregory F Sonnenberg;Hiroshi Takita;Sandra J Yokota

  • Human Lung Tumor Growth Established in the Lung and Subcutaneous Tissue of Mice with Severe Combined Immunodeficiency

    S Reddy;D Piccione;H Takita;R B Bankert

  • Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies.

    Richard B Bankert;Nejat K Egilmez;Stephen D Hess

  • THE NEXT GENERATION OF LIPOSOME DELIVERY SYSTEMS: RECENT EXPERIENCE WITH TUMOR-TARGETED, STERICALLY-STABILIZED IMMUNOLIPOSOMES AND ACTIVE-LOADING GRADIENTS

    R. M. Abra;R. B. Bankert;F. Chen;N. K. Egilmez

  • Follicular Lymphoma Intratumoral CD4+CD25+GITR+ Regulatory T Cells Potently Suppress CD3/CD28-Costimulated Autologous and Allogeneic CD8+CD25− and CD4+CD25− T Cells

    Shannon P. Hilchey;Asit De;Lisa M. Rimsza;Richard B. Bankert

  • Evaluation and optimization of different cationic liposome formulations for in vivo gene transfer.

    Nejat K. Egilmez;Yoshimi Iwanuma;Richard B. Bankert

  • Extracellular Vesicles Present in Human Ovarian Tumor Microenvironments Induce a Phosphatidylserine Dependent Arrest in the T Cell Signaling Cascade

    Raymond J Kelleher;Sathy Balu-Iyer;Jenni L Loyall;Anthony J Sacca

  • Sialic Acid-Dependent Inhibition of T Cells by Exosomal Ganglioside GD3 in Ovarian Tumor Microenvironments.

    Gautam N. Shenoy;Jenni Loyall;Charles S. Berenson;Charles S. Berenson;Raymond J. Kelleher

  • Immunogenicity of Subcutaneously Administered Therapeutic Proteins—a Mechanistic Perspective

    Anas M. Fathallah;Richard B. Bankert;Sathy V. Balu-Iyer

  • Human CD4+ T Cells Present Within the Microenvironment of Human Lung Tumors Are Mobilized by the Local and Sustained Release of IL-12 to Kill Tumors In Situ by Indirect Effects of IFN-γ

    Stephen D. Hess;Nejat K. Egilmez;Nicola Bailey;Timothy M. Anderson

  • Activation induces a rapid reorganization of spectrin in lymphocytes

    John K. Lee;John K. Lee;Jennifer D. Black;Elizabeth A. Repasky;Ralph T. Kubo

  • Human lung tumor-associated antigen identified as an extracellular matrix adhesion molecule.

    F A Chen;E A Repasky;R B Bankert

  • Human CD4+ Effector Memory T Cells Persisting in the Microenvironment of Lung Cancer Xenografts Are Activated by Local Delivery of IL-12 to Proliferate, Produce IFN-γ, and Eradicate Tumor Cells

    Lori Broderick;Sandra J. Yokota;Joshua Reineke;Edith Mathiowitz

Frequent Co-Authors

Elizabeth A. Repasky
Elizabeth A. Repasky Roswell Park Cancer Institute
Edith Mathiowitz
Edith Mathiowitz Brown University
Kunle Odunsi
Kunle Odunsi Roswell Park Cancer Institute
Leonard D. Shultz
Leonard D. Shultz Jackson Laboratory
Martin Morgan
Martin Morgan Roswell Park Cancer Institute
Paul K. Wallace
Paul K. Wallace Roswell Park Cancer Institute
Marc S. Ernstoff
Marc S. Ernstoff Roswell Park Cancer Institute
Nicholas J. Petrelli
Nicholas J. Petrelli Christiana Care Health System
Gerald P. Linette
Gerald P. Linette University of Pennsylvania
Ralph T. Kubo
Ralph T. Kubo Johns Hopkins University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, pursuing related healthcare degrees can open diverse career opportunities. Many students begin with foundational nursing programs, such as easiest absn program to get into, which offer an accelerated path into nursing. These programs are ideal for non-nurses looking to transition quickly into clinical roles.

Alternatively, individuals without a nursing background can explore online bsn programs for non nurses, which provide flexible options to earn a Bachelor of Science in Nursing online. These degrees serve as a stepping stone toward advanced practice and specialized fields.

For those aiming to advance their clinical expertise, accelerated formats like the accelerated nurse practitioner program can be an effective route. These programs enable faster progression into nurse practitioner roles, which often engage with immunological conditions and treatments.

Furthermore, obtaining acute care np certification is another pathway for advanced practitioners focusing on critical care settings. This specialization enhances expertise in managing acute immunological disorders and complex patient needs.

Best Scientists Citing Richard B. Bankert

Trending Scientists

Recently Published Articles